Core Insights - Silo Pharma has entered into a non-binding Letter of Intent with Allucent to conduct two Phase 1 studies for its SPC-15 nasal spray targeting PTSD and anxiety [1][2][3] Group 1: Clinical Development - The planned studies include an Open-Label, Single Ascending Dose (SAD) study and an Open-Label, Multiple Ascending Dose (MAD) study [1] - The collaboration with Allucent aims to leverage their expertise in clinical operations, pharmacovigilance, data management, and other areas to support the execution of the Phase 1 program [2][3] Group 2: Product Information - SPC-15 is an investigational intranasal serotonin 5-HT4 receptor agonist designed for stress-induced psychiatric conditions, primarily PTSD and anxiety, utilizing a soft mist nasal spray for rapid brain action [4] - The product is in preclinical stages and is being developed in partnership with Columbia University, with plans for an accelerated FDA approval pathway [4] Group 3: Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved conditions such as stress-induced psychiatric disorders and chronic pain [5] - The company's portfolio includes other innovative programs targeting fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis [5]

Tonix Pharmaceuticals (TNXP) entered into a securities purchase agreement with Point72 for the purchase and sale of 615,025 shares of its common stock at an offering price of $16.26 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 615,025 shares of common stock at a purchase price of $16.259 per pre-funded warrant, which equals the offering price per share of the common stock less the $0.001 per share exercise price of each pre-funded warrant. The clos ...

Core Viewpoint - Neurothera Labs Inc. has received a patent from the Israel Patent Office for its proprietary combination of opioids and N-acylethanolamines, aimed at enhancing the therapeutic effects of opioids while reducing side effects [1][2]. Group 1: Patent and Technology - The newly granted patent in Israel complements existing patents in Europe, Japan, Australia, and Canada, thereby strengthening the global intellectual property protection for Neurothera's opioid-based platform [2]. - The patented technology utilizes N-acylethanolamines, such as palmitoylethanolamide (PEA), to enhance opioid analgesia through synergistic mechanisms, allowing for effective pain relief at lower doses [2]. Group 2: Research and Efficacy - A pre-clinical study evaluated the nociceptive effect of PEA combined with opiates like oxycodone, demonstrating that the proprietary drug combination could reduce adverse psychoactive effects associated with oxycodone [3][4]. - The study found that PEA not only mitigated some negative side effects of oxycodone but also prolonged its analgesic effects across all doses tested [4]. Group 3: Market Context - The global market for oxycodone drugs is projected to be valued between $5.5 billion and $5.7 billion in 2024, highlighting the significant sales potential despite the risks associated with opioid use [5]. - The "opioid-sparing" effect of Neurothera's combination may lead to reduced opioid dosages, potentially addressing issues like addiction and respiratory depression [6]. Group 4: Company Perspective - The CEO of Neurothera emphasized the importance of the patent grant, which validates the advantages of their proprietary combination in providing effective pain relief while ensuring patient safety [7].

Sign in to access your portfolio Sign in ...

Core Viewpoint - PharmaCielo Ltd. has successfully revoked the failure to file cease trade order (FFCTO) and is set to resume trading on the TSX Venture Exchange after filing its required financial documents [2][3]. Financial Performance - For the six months ended September 30, 2025, PharmaCielo reported revenue of $1,212,000, a decrease from $2,113,000 in the same period of 2024 [4]. - The company recorded an adjusted EBITDA loss of $531,000, improving from a loss of $2,218,000 year-over-year [4]. - The net loss for the period was $2,687,000, down from $5,219,000 in the previous year, with a net loss per share of $0.014 compared to $0.031 [4]. Corporate Developments - The Ontario Securities Commission has revoked the FFCTO issued on August 5, 2025, allowing the company to move forward with its operations [2]. - The company has strengthened its balance sheet and streamlined operations in Colombia, aligning commercial efforts with the growing demand for high-quality cannabis products [3]. Debt and Financing - PharmaCielo has an aggregate principal balance of $2,150,000 in secured bridge loans from related parties, with an interest rate of 11% per annum [5]. - The company has issued 985 debenture units for total gross proceeds of $985,000, maturing on June 30, 2026, with each unit consisting of an 11% secured debenture and non-transferable common share purchase warrants [8]. Working Capital and Liabilities - As of September 30, 2025, PharmaCielo reported a working capital deficiency of $20,026,086, but has maintained adequate resources to support operations [10]. - Current liabilities include accounts payable and accrued liabilities of $5.73 million, current debt of $2.39 million, and current debentures of $15.43 million [13]. Future Outlook - The company aims to build consistent export volumes, deepen international partnerships, and selectively expand into profitable markets [3].

Core Insights - XOMA Royalty Corporation has amended its collaboration with Takeda, regaining a majority of the royalty interest in mezagitamab while diversifying its portfolio through a strategic royalty share transaction [1][2] Summary by Relevant Sections Collaboration with Takeda - The collaboration, originally established in 2006, has been amended to reduce Takeda's royalty and milestone payment obligations related to mezagitamab [1] - XOMA Royalty will now receive low to mid-single-digit royalties and milestone payments across nine development-stage assets in Takeda's externalized assets portfolio [1][2] Financial Implications - Prior to the amendment, XOMA Royalty held a mid-single-digit royalty and $16.25 million in potential milestones for mezagitamab [3] - Post-amendment, XOMA Royalty will retain a low single-digit royalty entitlement and up to $13.0 million in milestones for mezagitamab [3] Development-Stage Assets - The nine development-stage assets include: - **Osavampator**: Developed by Neurocrine Biosciences for major depressive disorder [4] - **Volixibat**: Developed by Mirum Pharmaceuticals for primary sclerosing cholangitis and primary biliary cholangitis [5] - **OHB-607**: A recombinant human IGF-1/IGFBP-3 for preventing bronchopulmonary dysplasia in premature infants, along with other early-stage assets from Oak Hill Bio [6] - **REC-4881**: An investigational MEK1/2 inhibitor for familial adenomatous polyposis, affecting approximately 50,000 people in the U.S. and Europe [7]

Acquisition and Business Strategy - Meta is set to acquire Manus, a Singapore-based AI startup specializing in general-purpose AI agents, to enhance its consumer and business product offerings with advanced AI capabilities [3] - The financial terms of the acquisition have not been disclosed, but Manus has achieved a $125 million annual revenue run rate shortly after launching its subscription-based AI agent services [4] - This acquisition aligns with Meta CEO Mark Zuckerberg's focus on AI infrastructure and monetization strategies beyond metaverse initiatives, marking the company's fifth AI-related acquisition in 2025 [5] Industry Developments - Boeing has secured an $8.6 billion contract from the U.S. Air Force to produce F-15 fighter jets for the Israeli Air Force, with the contract including options for additional aircraft [6] - The contract involves the design, integration, and delivery of 25 new F-15IA aircraft, with work expected to be completed by the end of 2035 [6] - Novo Nordisk has reduced the price of its GLP-1 medication Wegovy in China by nearly 50% for its two highest dosage strengths, in anticipation of increased competition from generics following the expiration of its patent in March 2026 [7][8]

“We expect the minutes to the December meeting to note ongoing disagreement among FOMC participants about the appropriate policy path over the near term,” Goldman Sachs economists wrote in a note this week.Today, market watchers will pay close attention to the publication of the minutes from the Fed’s December 9-10 meeting. The minutes will be scrutinized to assess policymakers’ appetite for additional rate cuts. The FOMC lowered its benchmark rate this month for the third time in a row, though officials’ m ...

These high-octane dividend stocks -- sporting an average yield of 11.25% -- have the catalysts needed to sustainably pad the pocketbooks of income seekers.For more than a century, Wall Street has proven it's a bona fide wealth-creating machine. With thousands of publicly traded companies and exchange-traded funds to choose from, there's a good chance one or more securities can help you reach your financial goals.But not all investment strategies are created equally on Wall Street. According to a comprehensi ...

Core Viewpoint - Newsmax, despite having over 50 million regular viewers in the U.S., faces significant competition and challenges in the market, particularly from larger players like Fox Corp, and is predicted to underperform compared to other stocks in the next five years [1][2]. Group 1: Newsmax Overview - Newsmax has a market capitalization of approximately $1.1 billion and has recently expanded into Europe and the Middle East, which may increase its audience [1][2]. - The company reported a net loss of $4.1 million in the third quarter of 2025, indicating ongoing profitability challenges [7]. Group 2: Competitor Analysis - Fox Corp - Fox Corp, Newsmax's largest competitor, has a market cap of nearly $31 billion, significantly larger than Newsmax's [4]. - In the latest quarter, Fox reported a profit of $690 million, while Newsmax's revenue growth is in low single-digit percentages [7]. - Fox's shares have a price-to-sales ratio of 1.8, which is more attractive compared to Newsmax's forward sales multiple of 6 [7]. Group 3: Competitor Analysis - Mirum Pharmaceuticals - Mirum Pharmaceuticals has a market cap of around $4 billion and reported a revenue increase of 47% year-over-year in the third quarter, driven by its liver disease drug Livmarli [8][9]. - The company is optimistic about its pipeline, including potential blockbuster drugs and plans to acquire Bluejay Therapeutics, which could enhance its portfolio [11][12]. Group 4: Competitor Analysis - The Trade Desk - The Trade Desk, a leading advertising technology company, has a market cap of $19 billion and is expected to outperform Newsmax in the long term [13][15]. - The Trade Desk's growth opportunities are bolstered by the rise of ad-supported connected TV and international market expansion [15].